A logo

Agilent Technologies Inc. (A)

$156.30

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on A

Market cap

$44.14B

EPS

4.98

P/E ratio

31.2

Price to sales

6.07

Dividend yield

0.653%

Beta

1.247215

Price on A

Previous close

$155.41

Today's open

$153.69

Day's range

$152.12 - $159.94

52 week range

$108.35 - $160.27

Profile about A

CEO

Padraig Mcdonnell

Employees

18000

Headquarters

Santa Clara, CA

Exchange

New York Stock Exchange

Shares outstanding

282431944

Issue type

Common Stock

A industries and sectors

Healthcare

Biotechnology & Life Sciences

News on A

Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore

Agilent Technologies (NYSE:A | A Price Prediction) heads into a pivotal earnings setup for retirement-oriented portfolios, with a company-confirmed Q3 2026 report after the close on Aug.

news source

24/7 Wall Street • 20 hours ago

news preview

Exploring Analyst Estimates for Agilent (A) Q3 Earnings, Beyond Revenue and EPS

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.

news source

Zacks Investment Research • 20 hours ago

news preview

MDT vs. A: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Agilent Technologies (A). But which of these two stocks presents investors with the better value opportunity right now?

news source

Zacks Investment Research • Aug 18, 2026

news preview

Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea.

news source

Business Wire • Jul 29, 2026

news preview

Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo.

news source

Business Wire • Jul 28, 2026

news preview

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD.

news source

Business Wire • Jul 23, 2026

news preview

Agilent Increases Its Investment in HALO X-ray Technologies

NOTTINGHAM, England--(BUSINESS WIRE)-- #AgilentTechnologies--Multimillion dollar investment round to enable HALO to complete regulatory approval of its advanced security screening technology.

news source

Business Wire • Jul 20, 2026

news preview

Dividend Champion, Contender, And Challenger Highlights: Week Of July 19

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.

news source

Seeking Alpha • Jul 18, 2026

news preview

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb'.

news source

Business Wire • Jul 14, 2026

news preview

Agilent Strengthens Biopharma Growth Prospects With AI Expansion

A enhances AI-powered lab software, automation and digital workflows to support drug discovery, biopharma research and long-term growth.

news source

Zacks Investment Research • Jul 9, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Agilent Technologies Inc.

Open an M1 investment account to buy and sell Agilent Technologies Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in A on M1